DOWNSTREAM PROCESSING FEATURED ARTICLES
-
Genetic Immunity Receives GMP Certification For In-House Manufacturing Facility
Genetic Immunity (OTCBB: PWRV) is pleased to announce the GMP approval of its manufacturing facility. The development of the GMP manufacturing process and the facility was financed from a $4 million grant received from the Hungarian Office for Innovation and Technology.
-
Ablynx And Its Partner Advance Nanobody Candidate ALX-0751 In Pre-Clinical Development
Ablynx [Euronext Brussels: ABLX] today announced that they have advanced the Nanobody(®) candidate ALX-0751, together with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, into pre-clinical development in the field of oncology.
-
Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies Of ETI-204 For Treatment Of Inhalational Anthrax
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been awarded additional funding from the U.S. Government, valued at $14.5 million, to support expanded human safety studies of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection following a biowarfare attack.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Continuous Harvesting Of Extra-Cellular Proteins From Mammalian Cell Cultures Utilizing Small-Scale Perfusion
The use of a small-scale cell culture system not only maximizes the production of valuable protein but also avoids the high capital cost associated with system scale-up. Continuous harvesting can provide significant improvements in protein yields when compared to those of typical batch operations.
-
Biomanufacturing Complexity
This white paper addresses one of the most serious challenges facing biomanufacturing professionals today - how to understand and then deal with the extreme complexity associated with biotechnology manufacturing.
-
White Paper: Computrac® Moisture Analysis Made Simple When people aren’t feeling their best they often turn to medicine for relief from the symptoms that are associated with being ill. The public trusts that the products by pharmaceutical companies will not only make them feel better but will also not have harmful side effects.
-
Protein A Alternatives: Mixed Mode Resins For High Throughput mAb Feedstocks
Mixed mode resins can serve as an alternative to protein A in intermediate processing. Implementation of mixed mode resins can reduce water required for filtration and time for column loading.
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.
-
Quality By Design In Biomanufacturing
QbD is increasingly required in our industry, but there are still gaps in understanding how QbD applies to the biomanufacturing process.